BioInsights - Feeder free expansion of a clinically relevant number of human NK cells

Feeder free expansion of a clinically relevant number of human NK cells

Cell & Gene Therapy Insights 2022; 8(10), 1285.

DOI: 10.18609/cgti.2022.189

Published: 10 November 2022
Poster
Erica Heipertz

Over the last decade, CAR-T cell therapy has emerged as a revolutionary treatment for blood cancers. However, as we begin to look forward to other immunotherapy options, one that is gaining increased attention is NK cell therapy. NK cells have several advantages over T cells, including their ability to function in an antigen-independent manner, which makes them a viable option for an allogeneic, ‘off the shelf’ therapy. NK cell therapy also has relatively few side effects, potentially, and recent studies suggest it may be a viable therapeutic option for solid tumors.